Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly Send to Friend Enquire before Buying Electronic (PDF)   Site License   Enterprisewide   Competitor Analysis: Anti-Infective Peptides La Merie, Jan 2009, Pages: 41   Description     Table of Contents        Enquire before Buying    Send to a Friend   The present Competitive Intelligence Report about Anti-Infective Peptides used to treat bacterial, viral and fungal infections provides a competitor evaluation in the field of R&D projects with anti-infective peptides as of January 2009. Stages of the anti-infective peptide R&D projects range from early research to market. Anti-Viral Peptides: Anti-viral peptides are used to treat infections such as HIV and AIDS, influenza incl. H5N1 strains, hepatitis C virus infections (HCV). Anti-Bacterial Peptides: Anti-bacterial peptides are used to treat infectious diseases such as complicated skin and skin structure infections (cSSSI), gram+ and gram- infections, prevention of catheter-related infections, otitis media, gingivitis and many more. Anti-Fungal Peptides: Anti-fungal peptides are used to treat infections such as oesophageal candidiasis, aspergillosis, oral candida infections, vaginal yeast infections and many more

		Top of page

All rights reserved. ? Copyright 2009 Research and Markets1    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster